Pentamethoxyamphetamine

PeMA
Clinical data
Other namesPeMA; 2,3,4,5,6-Pentamethoxyamphetamine; 2,3,4,5,6-PeMA; 2,6-Dimethoxy-TMA; 3,6-Dimethoxy-TMA-2
ATC code
  • None
Identifiers
  • 1-(2,3,4,5,6-pentamethoxyphenyl)propan-2-amine
CAS Number
PubChem CID
Chemical and physical data
FormulaC14H23NO5
Molar mass285.340 g·mol−1
3D model (JSmol)
  • CC(CC1=C(C(=C(C(=C1OC)OC)OC)OC)OC)N
  • InChI=1S/C14H23NO5/c1-8(15)7-9-10(16-2)12(18-4)14(20-6)13(19-5)11(9)17-3/h8H,7,15H2,1-6H3
  • Key:CDUJLDXLXICILS-UHFFFAOYSA-N

Pentamethoxyamphetamine (PeMA), also known as 2,3,4,5,6-pentamethoxyamphetamine (2,3,4,5,6-PeMA), 2,6-dimethoxy-TMA, or 3,6-dimethoxy-TMA-2, is a chemical compound of the phenethylamine and amphetamine families related to the psychedelic drug mescaline (3,4,5-trimethoxyphenethylamine). It is the α-methyl or amphetamine derivative of pentamethoxyphenethylamine (PeMPEA). The compound does not seem to have been tested in animals or humans. However, the related drug PeMPEA is known to be behaviorally active in animal studies. PeMA was first described in the scientific literature by Alexander Shulgin by 1969. It is a controlled substance in Canada under phenethylamine blanket-ban language.

See also